LETTER TO THE EDITOR
Possible effectiveness of switching biologics from adalimumab to certolizumab pegol in pyoderma gangrenosum
Minoru Kimura,
Minoru Kimura
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Akihiko Uchiyama,
Corresponding Author
Akihiko Uchiyama
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Correspondence
Akihiko Uchiyama, Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22, Showa, Maebashi, Gunma 371-8511, Japan.
Email: [email protected]
Search for more papers by this author Yukie Endo,
Yukie Endo
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Masahito Yasuda,
Masahito Yasuda
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Sei-ichiro Motegi,
Sei-ichiro Motegi
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author
Minoru Kimura,
Minoru Kimura
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Akihiko Uchiyama,
Corresponding Author
Akihiko Uchiyama
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Correspondence
Akihiko Uchiyama, Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22, Showa, Maebashi, Gunma 371-8511, Japan.
Email: [email protected]
Search for more papers by this author Yukie Endo,
Yukie Endo
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Masahito Yasuda,
Masahito Yasuda
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author Sei-ichiro Motegi,
Sei-ichiro Motegi
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this author
First published: 19 August 2024
No abstract is available for this article.
| Filename |
Description |
| jde17429-sup-0001-TableS1.xlsxExcel 2007 spreadsheet
, 12.8 KB |
Table S1.
|
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018; 77: 228–233.
- 2Yamakana K. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: a review. J Dermatol. 2024; 51: 172–179.
- 3Yamamoto T, Yamasaki K, Yamanaka K, Komine M, Kawakami T, Yamamoto O, et al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol. 2023; 50: e253–e275.
- 4Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009; 348: 36–41.
